Market Spotlight: Esophageal Cancer
Market Spotlight: Esophageal Cancer
$1,318.00
This Market Spotlight report covers the esophageal cancer market, comprising key marketed and pipeline drugs, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the esophageal cancer market, comprising key marketed and pipeline drugs, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals.
Key Takeaways:
- Datamonitor Healthcare estimates that in 2017, there were 488,800 incident cases of esophageal cancer worldwide, and expects that number to increase to 534,700 incident cases by 2026.
- Incidence is higher in males compared to females, and is highest in the Asia region. Merck’s Keytruda and Pinnacle Biologics’ Photofrin are the only marketed drugs for esophageal cancer. These drugs are administered via the intravenous route.
- The majority of industry-sponsored drugs in active clinical development for esophageal cancer are in Phase II. Therapies in development for esophageal cancer focus on a wide variety of targets. The majority of pipeline drugs are administered intravenously, while three drugs are being tested in oral formulations.
- The only high-impact upcoming event in the esophageal cancer space is topline Phase III trial results for Opdivo. The overall likelihood of approval of a Phase I solid tumors asset is 5.6%, and the average probability a drug advances from Phase III is 40%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
- There have been nine licensing and asset acquisition deals involving esophageal cancer drugs during 2014–19. The $1,456m drug development collaboration agreement signed in 2015 between Eli Lilly and Innovent Biologics to support the development and potential commercialization of at least three cancer treatments was the largest deal.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for esophageal cancer have been in the early and mid-phases of development, with 91% of trials in Phase I–II, and only 9% in Phase III–IV.
- The US has a substantial lead in the number of esophageal cancer clinical trials globally. The UK leads the major EU markets, while China has the top spot in Asia.
- Clinical trial activity in the esophageal cancer space is dominated by completed trials. Sanofi has the highest number of completed clinical trials for esophageal cancer, with 90 trials.
- Roche leads industry sponsors with the highest number of clinical trials for esophageal cancer, followed by Sanofi.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Surgery
9 Radiation therapy
9 Endoscopic therapy
10 Chemotherapy
10 Targeted therapy
10 Immunotherapy
12 EPIDEMIOLOGY
15 MARKETED DRUGS
17 PIPELINE DRUGS
23 RECENT EVENTS AND ANALYST OPINION
23 Keytruda for Esophageal Cancer (January 14, 2019)
24 Opdivo for Esophageal Cancer (January 9, 2019)
26 Keytruda for Esophageal Cancer (November 14, 2018)
27 Keytruda for Esophageal Cancer (June 3, 2018)
30 KEY UPCOMING EVENTS
31 KEY REGULATORY EVENTS
31 Keytruda Adds Esophageal Cancer Indication
31 Chugai Acquires Selected Rights to Oncolys’ Telomelysin
31 Merck’s Keytruda Shows Utility In Subset Of Esophageal Cancer
32 PROBABILITY OF SUCCESS
33 LICENSING AND ASSET ACQUISITION DEALS
34 PARENT PATENTS
35 CLINICAL TRIAL LANDSCAPE
36 Sponsors by status
37 Sponsors by phase
39 BIBLIOGRAPHY
39 Prescription information
40 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in incident cases of esophageal cancer, 2017–26
14 Figure 2: Incident cases of esophageal cancer, by gender, 2017
17 Figure 3: Overview of pipeline drugs for esophageal cancer in the US
18 Figure 4: Pipeline drugs for esophageal cancer, by company
18 Figure 5: Pipeline drugs for esophageal cancer, by drug type
18 Figure 6: Pipeline drugs for esophageal cancer, by classification
24 Figure 7: Keytruda for Esophageal Cancer (January 14, 2019): Phase III – KEYNOTE-181
26 Figure 8: Opdivo for Esophageal Cancer (January 9, 2019): Phase III – ATTRACTION-3
27 Figure 9: Keytruda for Esophageal Cancer (November 14, 2018): Phase III – KEYNOTE-181
29 Figure 10: Keytruda for Esophageal Cancer (June 3, 2018): Phase II – KEYNOTE-180
30 Figure 11: Key upcoming events in esophageal cancer
32 Figure 12: Probability of success in the esophageal cancer pipeline
33 Figure 13: Licensing and asset acquisition deals in esophageal cancer, 2014–19
34 Figure 14: Parent patents in esophageal cancer
35 Figure 15: Clinical trials in esophageal cancer
35 Figure 16: Top 10 drugs for clinical trials in esophageal cancer
36 Figure 17: Top 10 companies for clinical trials in esophageal cancer
36 Figure 18: Trial locations in esophageal cancer
37 Figure 19: Esophageal cancer trials status
38 Figure 20: Esophageal cancer trials sponsors, by phase
LIST OF TABLES
12 Table 1: Incident cases of esophageal cancer, 2017–26
16 Table 2: Marketed drugs for esophageal cancer
20 Table 3: Pipeline drugs for esophageal cancer in the US
23 Table 4: Keytruda for Esophageal Cancer (January 14, 2019)
25 Table 5: Opdivo for Esophageal Cancer (January 9, 2019)
26 Table 6: Keytruda for Esophageal Cancer (November 14, 2018)
28 Table 7: Keytruda for Esophageal Cancer (June 3, 2018)
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the